Pollack A E, Strauss J B
Department of Psychology, Box 1853, Brown University, Providence, RI 02912, USA.
Brain Res. 1999 May 8;827(1-2):160-8. doi: 10.1016/s0006-8993(99)01325-6.
Administration of dopamine agonists to 6-hydroxydopamine (6-OHDA) lesioned rats enhances the rotational response to subsequent administration of dopamine agonist, an effect called 'priming'. Previously, we have shown that 6-OHDA rats primed with three injections of the D1/D2 dopamine agonist apomorphine (0.5 mg/kg) permitted a challenge with an otherwise inactive dose of the D2 agonist quinpirole (0.25 mg/kg) to elicit robust rotational behavior and to induce Fos expression in striatoentopeduncular neurons. In this study, the time-course and role of N-methyl-d-aspartate (NMDA) glutamate receptors on apomorphine-priming of these D2 responses were investigated. The enhanced rotational behavior and striatal Fos expression observed following challenge with quinpirole (0.25 mg/kg) peaked 1 day following the third apomorphine priming injection and persisted, in reduced form, for at least 4 months. Pretreatment with the NMDA antagonists MK-801 or 3-[(+)-2-carboxypiperazin-4-yl]-propyl-1-phosphonate (CPP) dose-dependently attenuated apomorphine-priming of quinpirole-mediated rotational behavior and striatal Fos induction compared to 6-OHDA rats primed with apomorphine alone. Taken together, these data suggest that priming of these D2-mediated responses in 6-OHDA rats develops rapidly, persists for several months, and is dependent on concomitant NMDA receptor stimulation. Since this priming effect resembles response fluctuations observed in patients with Parkinson's disease receiving long-term l-dihydroxyphenylalanine therapy, the results of the present study suggest that interventions that prevent the development of this enhanced response, such as NMDA antagonists, could prove useful in reducing the incidence these response fluctuations.
给6-羟基多巴胺(6-OHDA)损伤的大鼠注射多巴胺激动剂会增强其对随后注射多巴胺激动剂的旋转反应,这种效应称为“启动”。此前,我们已经表明,用三次注射D1/D2多巴胺激动剂阿扑吗啡(0.5mg/kg)启动的6-OHDA大鼠,在用原本无活性剂量的D2激动剂喹吡罗(0.25mg/kg)进行激发时,会引发强烈的旋转行为,并诱导纹状体-内苍白球神经元中Fos表达。在本研究中,研究了N-甲基-D-天冬氨酸(NMDA)谷氨酸受体对这些D2反应阿扑吗啡启动的时间进程和作用。在用喹吡罗(0.25mg/kg)激发后观察到的增强的旋转行为和纹状体Fos表达在第三次阿扑吗啡启动注射后1天达到峰值,并以减弱的形式持续至少4个月。与仅用阿扑吗啡启动的6-OHDA大鼠相比,用NMDA拮抗剂MK-801或3-[(+)-2-羧基哌嗪-4-基]-丙基-1-膦酸酯(CPP)预处理可剂量依赖性地减弱喹吡罗介导的旋转行为和纹状体Fos诱导的阿扑吗啡启动。综上所述,这些数据表明,6-OHDA大鼠中这些D2介导反应的启动迅速发展,持续数月,并且依赖于伴随的NMDA受体刺激。由于这种启动效应类似于接受长期左旋多巴治疗的帕金森病患者中观察到的反应波动,本研究结果表明,预防这种增强反应发展的干预措施,如NMDA拮抗剂,可能被证明有助于降低这些反应波动的发生率。